• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    11/17/25 4:30:47 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    cosm_8k.htm
    0001474167false00014741672025-11-172025-11-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) November 17, 2025

     

    Cosmos Health Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    000-54436

     

    27-0611758

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    5 AGIOU GEORGIOU, Pilea, Thessaloniki, Greece

     

    55438

    (Address of principal executive offices) 

     

    (Zip Code)

     

    Registrant’s telephone number, including area code (312) 865-0026

     

    (Former name or former address, if changed since last report.)

     

    Title of Each Class

     

    Trading Symbol

     

    Name of Each Exchange On Which Registered

    Common Stock, $.001 par value

     

    COSM

     

    The Nasdaq Stock Market LLC

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     

    On November 17, 2025, Cosmos Health Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference in this Item 2.02.

     

    ITEM 7.01 REGULATION FD DISCLOSURE.

     

    The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.

     

    In accordance with General Instruction B.2 to Form 8-K, the information set forth in the Items 2.02 and 7.01 and in Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.

     

    By furnishing this Current Report on Form 8-K, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including the statements made in Items 2.02 and 7.01 above and in Exhibit 99.1 hereto.

     

    ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

     

    (d) Exhibits

     

    Exhibit No.

     

    Description

     

     

     

    99.1

     

    Press Release issued by Cosmos Health Inc., dated November 17, 2025.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    2

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    COSMOS HEALTH INC.

     

     

     

     

    Date: November 17, 2025

    By:

    /s/ Georgios Terzis

    Georgios Terzis

     

    Chief Financial Officer

     

     

     

    3

     

    Get the next $COSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $175,000 worth of shares (353,321 units at $0.50), increasing direct ownership by 5% to 8,091,795 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/21/26 10:11:57 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/15/26 9:40:58 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

    CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece. During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved unit economics, with annual revenue per customer increasing by approximately 12% and profitability per customer improving by approximately 14%, driven by enhanced route density, optimize

    1/20/26 10:45:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

    CHICAGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research ("Zacks") has initiated coverage on the Company with a valuation of $4.50 per share, according to a research report published on January 13, 2026 and authored by analyst Brad Sorensen. Zacks highlighted Cosmos Health's diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-enabled initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation. Key Highlights from Zac

    1/14/26 11:25:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

    CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product's exclusive distributor in Greece. Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with appl

    1/5/26 9:30:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $175,000 worth of shares (353,321 units at $0.50), increasing direct ownership by 5% to 8,091,795 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/21/26 10:11:57 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/15/26 9:40:58 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

    S-3/A - Cosmos Health Inc. (0001474167) (Filer)

    12/29/25 5:15:18 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form 424B3 filed by Cosmos Health Inc.

    424B3 - Cosmos Health Inc. (0001474167) (Filer)

    12/19/25 5:12:36 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    12/18/25 10:23:22 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

    CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

    4/16/25 12:45:15 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

    CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

    12/26/24 1:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

    THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

    11/21/23 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Financials

    Live finance-specific insights

    View All

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

    CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

    1/21/25 3:00:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Issues Letter to Shareholders

    CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

    11/12/24 12:01:41 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Cosmos Health Inc.

    SC 13G - Cosmos Health Inc. (0001474167) (Subject)

    2/14/24 3:33:29 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care